References
Mankoff DA. A definition of molecular imaging. J Nucl Med 2007;48:18N.
Decristoforo C, Peñuelas I, Elsinga P, Ballinger J, Winhorst A, Verbruggen A, et al. Radiopharmaceuticals are special, but is this recognized? The possible impact of the new Clinical Trials Regulation on the preparation of radiopharmaceuticals. Eur J Nucl Med Mol Imaging 2014;41:2005-7.
Camici PG. Imaging of cardiac adrenergic innervation. Heart 2002;88:209-10.
Haubner R, Beer AJ, Wang H, Chen X. Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging 2010;37:S86-103.
Wu C, Li F, Niu G, Chen X. PET imaging of inflammation biomarkers. Theranostics 2013;3:448-66.
Nahrendorf M, Sosnovik DE, French BA, Swirski FK, Bengel F, Sadeghi MM, et al. Multimodality cardiovascular molecular imaging. Part II. Circ Cardiovasc Imaging 2009;2:56-70.
Boellard R, Delgado-Bolton R, Oyen W, Giammarile F, Tatsch K, et al. FDG PET/CT: EANM procedural guidelines version 2.0. Eur J Nucl Med Mol Imaging 2015, in press.
Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden Ch. 2013 ESC Guidelines on the management of stable coronary artery disease. Eur Heart J 2013;34:2949-3003.
Erbel R, Aboyans V, Boileau C, Bosone E, Bartolomeo R, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J 2014;35:2873-926.
McMurray J, Adamopoulos S, Anker S, Auricchio A, Boehm M, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2012;33:1787-847.
Gladding P, Cave A, Zareian M, Smith K, Hussan J, et al. Open access integrated therapeutic and diagnostic platforms for personalized cardiovascular medicine. J Personal Med 2013;3:2013-237.
Kirchhof P, Sipido KR, Cowie MR, Eschenhagen T, Fox KAA, et al. The continuum of personalized cardiovascular medicine: A position paper of the European Society of Cardiology. Eur Heart J 2014;35:3250-7.
Mullard A. In 2012 FDA drug approvals. Nat Rev Drug Discov 2013;12:87-90.
Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: A prospective clinical trial. Lancet 2014;383:705-13.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Carrió, I. Debate: Molecular cardiac imaging is ready for the prime time con between wishful thinking and reality. J. Nucl. Cardiol. 23, 64–66 (2016). https://doi.org/10.1007/s12350-015-0124-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12350-015-0124-5